Variability in human embryonic development and its implications for the susceptibility to environmental teratogenesis

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 85, Issue 8, 2009, Pages 661-666

  Shiota, Kohei ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Developmental stage; Environmental teratogenesis; Gestational age; Human embryo; Teratogenic susceptibility; Variability

Indexed keywords

DEVELOPMENTAL STAGE; EMBRYO DEVELOPMENT; FERTILIZATION; GESTATIONAL AGE; HUMAN; HUMAN EMBRYO; NONHUMAN; OVULATION; PRENATAL DEVELOPMENT; PRIORITY JOURNAL; REVIEW; TERATOGENESIS;

EMBRYO, MAMMALIAN; EMBRYONIC DEVELOPMENT; ENVIRONMENTAL EXPOSURE; FEMALE; GESTATIONAL AGE; HUMANS; PREGNANCY; TERATOGENS; THALIDOMIDE;

ANIMALIA;

EID: 68949113826     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20596     Document Type: Review

References (19)

1. Dickey RP, Gasser RF. 1993. Ultrasound evidence for variability in the size and development of normal human embryos before the tenth post-insemination week after assisted reproductive technologies. Hum Reprod 8:331-337.
2. Endo A, Watanabe T. 1988. Interlitter variability in fetal body weight in mouse offspring from continuous, overnight, and short-period matings. Teratology 37:63-67. (Pubitemid 18061552)
3. Fuhrmann W, Werrner E. 1965. Pharmakogene embryopathien - Ein Beitrag zum Thalidomidproblem. Z Ärztl Forbild 54:844.
4. Kajii T, Kida M, Takahashi K. 1973. The effect of thalidomide intake during 113 human pregnancies. Teratology 8:163-166.
5. Kobyletzki D von, Gallen J. 1970. Zur Vorhersage des embryonalen Entwicklungszustandes des Menschen. Arch Gynäk 209:293-304.
6. Lenz W, Knapp K. 1962. Die Thalidomid-Embryopathie. Dtsch Med Wochenschr 87:1232-1242.
7. Neubert D, Blankenburg G, Chahoud I, et al. 1986. Results of in vivo and in vitro studies for assessing prenatal toxicity. Environ Health Perspect 70:89-103. (Pubitemid 17034341)
8. Neubert D, Chahoud I, Platzek T, Meister R. 1987. Principles and problems in assessing prenatal toxicity. Arch Toxicol 60:238-245. (Pubitemid 17081724)
9. Neubert D, Heger W, Merker HJ, et al. 1988. Embryotoxic effects of thalidomide derivatives in the non-human primate Callithrix jacchus. II. Elucidation of the susceptible period and of the variability of embryonic stages. Arch Toxicol 61:180-191.
10. Nishimura H. 1975. Prenatal versus postnatal malformations based on the Japanese experience on induced abortions in the human being. In: Aging gametes. Blandau RJ, editor. Aging gamates. Basel, Switzerland: S Karger. pp. 349-368.
11. Nishimura H, Takano K, Tanimura T, Yasuda M. 1968. Normal and abnormal development of human embryos: first report of the analysis of 1,213 intact embryos. Teratology 1:281-290.
12. Nowack E. 1965. Die sensible Phase bei der Thalidmid-Embryopathie. Humangenetik 1:516-536.
13. O'Rahilly R. 1973. Developmental stages in human embryos. Part A: embryos of the first three weeks (stages 1 to 9). Washington, DC: Carnegie Institution of Washington.
14. O'Rahilly R, Müller F. 1987. Developmental stages in human embryos. Washington, DC: Carnegie Institution of Washington.
15. Shiota K. 1991. Development and intrauterine fate of normal and abnormal human conceptuses. Congenit Anom (Kyoto) 31:67-80.
16. Shiota K, Fischer B, Neubert D. 1988. Variability in the development of human embryos. In: Neubert D, Merker H-J, Hendrickx AG, editors. Non-human primates - developmental biology and toxicology. Berlin and Vienna: Ueberreuter. pp. 191-203.
17. Thiel R, Chahoud I, Jürgens M, Neubert D. 1993. Time-dependent differences in the development of somites of four different mouse strains. Teratog Carcinog Mutagen 13:247-257. (Pubitemid 23343161)
18. Weicker H, Bachmann KD, Pfeiffer RA, Gleiss J. 1962. Thalidomid- Embryopathie. Dtsch Med Wochenschr 87:1597-1607.
19. Wilson JG. 1973. Environment and birth defects. New York: Academic Press.